These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 23526368)

  • 1. Potential risks of pharmacy compounding.
    Gudeman J; Jozwiakowski M; Chollet J; Randell M
    Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extemporaneous Compounding: Selective Pharmacists with Separate Skill.
    Mohiuddin AK
    Innov Pharm; 2019; 10(4):. PubMed ID: 34007590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compounding pharmacy conundrum: "we cannot live without them but we cannot live with them" according to the present paradigm.
    Guharoy R; Noviasky J; Haydar Z; Fakih MG; Hartman C
    Chest; 2013 Apr; 143(4):896-900. PubMed ID: 23412546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applying Quality by Design Concepts to Pharmacy Compounding.
    Timko RJ
    Int J Pharm Compd; 2015; 19(6):453-63. PubMed ID: 26891559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacy compounding of high-risk level products and patient safety.
    Mullarkey T
    Am J Health Syst Pharm; 2009 Sep; 66(17 Suppl 5):S4-13. PubMed ID: 19710449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk and liabilities of prescribing compounded medications.
    Randell MD; Duffy PJ
    Postgrad Med; 2014 Jul; 126(4):178-80. PubMed ID: 25276868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient safety issues associated with the use of compounded medicines as alternatives to approved pharmaceutical products in Europe and how best practice can improve outcomes.
    Isles M
    Int J Risk Saf Med; 2020; 31(3):133-144. PubMed ID: 32538874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy.
    Pinkerton JV; Pickar JH
    Menopause; 2016 Feb; 23(2):215-23. PubMed ID: 26418479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacist-driven Food and Drug Administration incident surveillance and response program for compounded drugs.
    Janusziewicz AN; Glueck SN; Park SY; Nguyen DN; Rimmel SC; Cascio LA; Doh GY; Martin-Yeboah GF
    Am J Health Syst Pharm; 2021 Jul; 78(15):1438-1443. PubMed ID: 33889929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacy compounding primer for physicians: prescriber beware.
    Sellers S; Utian WH
    Drugs; 2012 Nov; 72(16):2043-50. PubMed ID: 23039281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA approved vs. Pharmacy compounded 17-OHPC-current issues for obstetricians to consider in reducing recurrent preterm birth.
    Gandell DL; Randell MD; Gudeman JL
    Curr Med Res Opin; 2020 Aug; 36(8):1393-1401. PubMed ID: 32544354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the Quality of Compounded Sterile Drug Products: A Historical Perspective.
    Cantrell SA
    Ther Innov Regul Sci; 2016 May; 50(3):266-269. PubMed ID: 30227062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence, determinants, and characteristics of extemporaneous compounding in Jordanian pharmacies.
    AlKhatib HS; Jalouqa S; Maraqa N; Ratka A; Elayeh E; Al Muhaissen S
    BMC Health Serv Res; 2019 Nov; 19(1):816. PubMed ID: 31703672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical compounding or pharmaceutical manufacturing? A regulatory perspective.
    Timko RJ; Crooker PE
    Int J Pharm Compd; 2014; 18(2):101-11. PubMed ID: 24881112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sterile compounding: clinical, legal, and regulatory implications for patient safety.
    Qureshi N; Wesolowicz L; Stievater T; Lin AT
    J Manag Care Spec Pharm; 2014 Dec; 20(12):1183-91. PubMed ID: 25443512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compounding for animal patients: contemporary issues.
    Lust E
    J Am Pharm Assoc (2003); 2004; 44(3):375-84; quiz 384-6. PubMed ID: 15191248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Practice of Compounding, Associated Compounding Regulations, and the Impact on Dermatologists.
    Quertermous J; Desai S; Harper J; Lebwohl M; Torres A; Kircik LH
    J Drugs Dermatol; 2018 Jul; 17(7):s17-s22. PubMed ID: 30005109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compounded non-FDA-approved menopausal hormone therapy prescriptions have increased: results of a pharmacy survey.
    Pinkerton JV; Constantine GD
    Menopause; 2016 Apr; 23(4):359-67. PubMed ID: 26645819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency, nature and determinants of pharmacy compounded medicines in Dutch community pharmacies.
    Buurma H; de Smet PA; van den Hoff OP; Sysling H; Storimans M; Egberts AC
    Pharm World Sci; 2003 Dec; 25(6):280-7. PubMed ID: 14689817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Description of outbreaks of health-care-associated infections related to compounding pharmacies, 2000-12.
    Staes C; Jacobs J; Mayer J; Allen J
    Am J Health Syst Pharm; 2013 Aug; 70(15):1301-12. PubMed ID: 23867487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.